Controlled delivery system

Patent metadata

Field	Value
Publication number	US-10434213-B2
Application number	US-201113042126-A
Country	US
Kind code	B2
Filing date	Mar 7, 2011
Priority date	Mar 5, 2010
Publication date	Oct 8, 2019
Grant date	Oct 8, 2019

Abstract

Provided herein are keratin compositions (e.g., keratin gels, scaffolds, particulates, and the like) including a compound of interest, useful for release and/or delivery of the compound of interest (e.g., in vivo or in vitro). In some embodiments, the composition is a composition formulated for controlled release of the compound of interest.

First claim

That which is claimed is:

1. A hydrogel composition for controlled release of a compound of interest, comprising:
a keratin composition selected from the group consisting of: keratose, kerateine, and combinations thereof; and
said compound of interest dispersed in said keratin composition and retained within said keratin composition through electrostatic interactions;
wherein said hydrogel composition has a pH of from 4 to 6 and said hydrogel composition is formed from said keratin composition, and the hydrogel composition at said pH does not precipitate the keratin composition and said compound of interest does not precipitate within the hydrogel composition,
wherein the controlled release of said compound of interest from said hydrogel composition is controlled by degradation of said keratin composition.

2. The hydrogel composition of claim 1 , wherein said keratin composition is selected from the group consisting of: acidic keratose, basic keratose, acidic kerateine, basic kerateine, and combinations thereof.

3. The hydrogel composition of claim 1 , wherein said keratin composition is selected from the group consisting of: α-keratose, γ-keratose, basic α-keratose, acidic α-keratose, basic γ-keratose, acidic γ-keratose, and combinations thereof.

4. The hydrogel composition of claim 1 , wherein said keratin composition is selected from the group consisting of: α-kerateine, γ-kerateine, basic α-kerateine, acidic α-kerateine, basic γ-kerateine, acidic γ-kerateine, and combinations thereof.

5. The hydrogel composition of claim 1 , wherein said hydrogel composition comprises from 0.5 to 50% by weight of said keratin composition selected from keratose, kerateine, and combinations thereof, and from 0.5 to 50% by weight of said compound of interest.

6. The hydrogel composition of claim 1 , wherein said compound of interest comprises a protein or peptide.

7. The hydrogel composition of claim 1 , wherein said compound of interest comprises an antibody or a fragment thereof.

8. The hydrogel composition of claim 1 , wherein said compound of interest comprises a growth factor.

9. The hydrogel composition of claim 1 , wherein said compound of interest comprises an antibiotic.

10. The hydrogel composition of claim 1 , wherein said compound of interest is ciprofloxacin or a derivative thereof.

11. The hydrogel composition of claim 1 formulated for topical administration.

12. The hydrogel composition of claim 1 formulated for parenteral administration.

13. The hydrogel composition of claim 1 formulated for release of said compound of interest over a time of from 1 to 48 hours.

14. The hydrogel composition of claim 1 formulated for release of said compound of interest over a time of from 1 to 180 days.

15. The hydrogel composition of claim 1 , wherein said keratin composition is a mixture of alpha and gamma kerateine.

16. The hydrogel composition of claim 15 , wherein said mixture of alpha kerateine and gamma kerateine is selected from the group consisting of: about 50% alpha-kerateine and about 50% gamma-kerateine, about 60% alpha-kerateine and about 40% gamma-kerateine, about 70% alpha-kerateine and about 30% gamma-kerateine, about 80% alpha-kerateine and about 20% gamma-kerateine, and about 90% alpha-kerateine and about 10% gamma-kerateine.

17. The hydrogel composition of claim 1 , wherein said compound of interest comprises a fluorinated quinoline antibiotic.

18. A method of administering a compound of interest to a subject in need thereof, said method comprising the steps of:
providing the hydrogel composition of claim 1 ; and
administering said hydrogel composition to said subject in a treatment effective amount.

19. The method of claim 18 , wherein said subject is a human subject.

20. A hydrogel composition comprising a reconstituted mixture of alpha kerateine and gamma kerateine and at least one compound of interest;
wherein said alpha kerateine comprises 45% to about 99% of the mixture;
wherein said hydrogel composition is formed from said mixture of alpha kerateine and gamma kerateine;
wherein said at least one compound of interest is retained within said mixture of alpha kerateine and gamma kerateine through electrostatic interactions;
wherein said hydrogel composition is formulated for controlled release of said at least one compound of interest over 1 to 180 days; and
wherein the controlled release of said at least one compound of interest from said hydrogel composition is controlled by degradation of the hydrogel composition formed from said mixture of alpha kerateine and gamma kerateine.

21. The hydrogel composition of claim 20 , wherein said mixture of alpha kerateine and gamma kerateine is selected from the group consisting of: about 50% alpha-kerateine and about 50% gamma-kerateine, about 60% alpha-kerateine and about 40% gamma-kerateine, about 70% alpha-kerateine and about 30% gamma-kerateine, about 80% alpha-kerateine and about 20% gamma-kerateine, and about 90% alpha-kerateine and about 10% gamma-kerateine.

22. The hydrogel composition of claim 20 , wherein said hydrogel composition is formulated as a sponge.

23. The hydrogel composition of claim 20 , wherein said hydrogel composition is formulated as a film.

24. A hydrogel composition for controlled release of a compound of interest, comprising:
a keratin composition comprising keratose; and
said compound of interest dispersed in said keratin composition and retained within said keratin composition through electrostatic interactions;
wherein said hydrogel composition has a pH of from 4 to 6 and said hydrogel composition is formed from said keratose, and the hydrogel composition at said pH does not precipitate the keratin composition and said compound of interest does not precipitate within the hydrogel composition,
wherein the controlled release of said compound of interest from said hydrogel composition is controlled by degradation of the keratose.

25. The hydrogel composition of claim 24 , wherein said keratose is alpha keratose.

Assignees

• Van Dyke Mark E
• Saul Justin M
• Smith Thomas L
• De Guzman Roche
• Univ Wake Forest Health Sciences

Inventors

• Van Dyke Mark E
• Saul Justin M
• Smith Thomas L
• De Guzman Roche

Classifications

• A61L2300/406

  Antibiotics · CPC title

• A61L2300/256

  Antibodies, e.g. immunoglobulins, vaccines · CPC title

• A61L27/227

  Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24 · CPC title

• A61L2300/414

  Growth factors · CPC title

• A61L15/44

  Medicaments · CPC title